Clinical Trial: Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery

Brief Summary: The investigators designed a prospective randomized study to compare the conventionally used sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.

Detailed Summary:
Sponsor: Baskent University

Current Primary Outcome: The incidence of adverse effects such as respiratory and hemodynamic events [ Time Frame: up to 24 hours postoperative ]

Original Primary Outcome: Same as current

Current Secondary Outcome: The sedation onset time with using BIS and recovery times during the procedure. [ Time Frame: up to 24 hours postoperative ]

Original Secondary Outcome: Same as current

Information By: Baskent University

Dates:
Date Received: May 11, 2015
Date Started: May 2015
Date Completion: July 2015
Last Updated: May 18, 2015
Last Verified: May 2015